Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
29 July 2022 |
Main ID: |
NCT03976076 |
Date of registration:
|
31/05/2019 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
|
Scientific title:
|
A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients |
Date of first enrolment:
|
April 15, 2020 |
Target sample size:
|
16 |
Recruitment status: |
Terminated |
URL:
|
https://clinicaltrials.gov/show/NCT03976076 |
Study type:
|
Interventional |
Study design:
|
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
Phase:
|
Phase 2
|
|
Countries of recruitment
|
United States
| | | | | | | |
Contacts
|
Name:
|
Brandon Choi |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Sponsor Management |
| | |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|